REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.01
Bid: 2.00
Ask: 2.15
Change: 0.055 (2.72%)
Spread: 0.15 (7.50%)
Open: 2.07
High: 2.07
Low: 1.91
Prev. Close: 2.02
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Alphawave teams with Intel; Cadence's Amapa progress

Mon, 07th Feb 2022 18:29

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Alphawave IP Group PLC - designs and licences chip technology - Teams with Intel Corp's Intel Foundry Services. Intel Foundry is a unit of Santa Clara, California-based Intel. It manufactures third-party chips. "By combining Intel's manufacturing and operational prowess with Alphawave IP's technology leadership in connectivity solutions, the partnership will enable some of the world's largest chip companies and hyperscalers to build the most advanced semiconductor devices in 2022 and beyond," Alphawave says.

----------

Cadence Minerals PLC - London-based investor in mineral resources - Says required contractual and regulatory documentation completed and filed at Amapa iron ore project, sealing process and ensuring Cadence now owns 20% of the Brazil-based project. Cadence notes Anglo American PLC, a previous owner, valued the asset at USD1.2 billion and impaired it at USD600 million back in its 2012 accounts.

----------

Oilex Ltd - Perth-based company focused on the development of natural gas assets - India's Ministry of Environment, Forest & Climate Change confirms decision to approve environmental clearance for Cambay field.

----------

Hunting PLC - London-based supplier to oil and gas industry - Refinances core borrowing facilities and enters into USD150 million asset based lending facility with Wells Fargo and HSBC. New facility has four-year term and replaces USD160 million revolving credit facility. "The ABL facility contains an accordion feature of up to a further USD50 million which is accessible subject to further credit approval from the relevant lenders, enabling the company to increase the total facility quantum to USD200 million," Hunting adds.

----------

Helium One Global Ltd - London-based exploration & development company - Begins electrical resistivity tomography at Rukwa asset. Survey will probe area identified from phase I and phase II 2D seismic surveys. Will also investigate "surface helium anomalies identified in recently completed multispectral satellite spectroscopy study".

----------

Wildcat Petroleum PLC - targeting investment opportunities in businesses and assets within the upstream sector of the petroleum industry, including the use of blockchain within the sector - Names PETRO-TEC as petroleum consultants. "PT will be able to devise, implement, run and evaluate appropriate field development projects alongside WCAT," company says.

----------

Insig AI PLC - London-based machine learning and data science firm which serves the asset management industry, formerly known as Catena Group PLC - Picked for PwC's Scale FinTech programme, aiming to give access to new opportunities within the accounting firm and its clients. "After an extensive selection process, Insig AI was one of only nine companies this year chosen from more than 700 applicants from around the world. Insig AI is also the only FinTech with ESG expertise on the programme," Insig says.

----------

Octopus Renewables Infrastructure Trust PLC - London-based investment company focused on renewable energy assets in Europe and Australia - Declares 1.25 pence per share dividend for fourth quarter ended December 31. Notes 2021 payout totals 5.0p per share, meeting target. For 2022, it eyes 5.24p payout, up 4.8%.

----------

ImmuPharma PLC - London-based drug discovery and development company - Says UK Medical & Health Products Regulatory Agency approves pharmacokinetic study Lupuzor in Lupus patients. "Volunteers have been selected and approved for inclusion in the PK study," company says. Vounteer dosing to begin on February 15 and study on track to deliver results by end of first quarter.

----------

Ondine Biomedical Inc - Vancouver, Canada-based life sciences company focused on photodisinfection-based therapies - Treats first patients in phase 2 of US Food & Drug Administration nasal photodisinfection exploratory trial. "The study will evaluate how effectively the treatment eradicates pathogens -Staphylococcus aureus - in the nose, and the occurrence of surgical site infections within 30 days of surgery," Ondine adds.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
14 Mar 2019 10:41

ImmuPharma Preparing For Lupuzor Drug Managed Access Programme

LONDON (Alliance News) - ImmuPharma PLC said it is in final preparations to open a managed access programme for its lupus drug Lupuzor to patients in Europe.Shares in the drug discovery and

Read more
26 Feb 2019 12:06

ImmuPharma upbeat on product from subsidiary Ureka

(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced on Tuesday that on 25 February, the peer reviewed research journal Nature Communications published a fundamental scientific publication on the proprietary technology 'Urelix' from its subsidiary Ureka.

Read more
31 Dec 2018 12:00

ImmuPharma and Incanthera extend exclusivity period for Nucant agreement

(Sharecast News) - Specialist drug discovery and development company ImmuPharma updated the market on its clinical development collaboration agreement for its 'Nucant' cancer programme on Monday, with specialist oncology development partner Incanthera.

Read more
7 Dec 2018 11:26

ImmuPharma Progressing To Make Lupuzor Available To Patients

LONDON (Alliance News) - ImmuPharma PLC on Friday said it is currently in the process of making Lupuzor, its drug for the treatment of lupus, available to patients via its managed access drug said

Read more
7 Dec 2018 08:09

Immupharma plots patient recruitment for Lupzor trials

(Sharecast News) - Drug discovery and development outfit Immupharma has progressed its managed access programme on Lupzor as planned, with patient recruitment in France and the UK expected to follow the firm's analysis of regulatory processes across the EU.

Read more
26 Sep 2018 13:55

ImmuPharma still banking on Lupuzor even after failed trial

(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced its interim results for the six months ended 30 June on Wednesday - a period in which its revenue remained negligible at £0.07m, but its drug candidate 'Lupuzor' demonstrated a superior response rate over placebo in its primary analysis on the full set of 202 patients.

Read more
26 Sep 2018 12:53

Wednesday broker round-up

(Sharecast News) - IAG: UBS downgrades to neutral with a target price of 705p.

Read more
26 Sep 2018 12:40

ImmuPharma Interim Loss Widens On Higher Costs And Lower Revenue

LONDON (Alliance News) - ImmuPharma PLC said on Wednesday it continues to progress its lupus treatment Lupuzor, as it saw a widened loss for the first half of 2018 due to higher costs and lower a

Read more
9 Sep 2018 10:59

Sunday share tips: Immupharma, PCF Bank

(Sharecast News) - For the 'Inside the City' column in the Sunday Times, Sabah Meddings wrote a "cautionary tale" about former biotech darling Immupharma, which last year saw its shares rise 227% over a year.

Read more
7 Sep 2018 11:43

ImmuPharma Inks Pact With Incanthera For Nucant Cancer Programme

LONDON (Alliance News) - ImmuPharma PLC said Friday it signed a clinical development collaboration for the Nucant cancer programme with Incanthera Ltd, a specialist oncology development the terms

Read more
7 Sep 2018 08:10

Immupharma to make 'blockbuster' lupus treatment available

(Sharecast News) - Pharmaceutical firm ImmuPharma on Friday signed an agreement for a managed access programme (MAP) for its "ground-breaking" new lupus treatment, Lupuzor.

Read more
14 Jun 2018 12:02

Immupharma Says P140 Peptide Shows Positive Results In CIDP Treatment

LONDON (Alliance News) - ImmuPharma PLC said Thursday that its pre-clinical studies of the P140 peptide showed positive results in the treatment of chronic inflammatory demyelinating were trading

Read more
29 May 2018 09:40

ImmuPharma Excited Despite Widened Loss As Lupuzor Makes Good Results

LONDON (Alliance News) - ImmuPharma PLC said Tuesday it continues to be "excited" by its future potential despite a widened loss for 2017.The drug development company reported a a

Read more
23 Mar 2018 11:17

ImmuPharma Prepares To Report Lupuzor Study Results In April

LONDON (Alliance News) - Drug development company ImmuPharma PLC said on Friday it has been informed by Simbec-Orion that the data-base lock for the Lupuzor pivotal phase III

Read more
25 Jan 2017 14:33

ImmuPharma trial of Lupuzor continuing smoothly

(ShareCast News) - Specialist drug discovery and development company ImmuPharma provided further details of patient participation on Wednesday, following confirmation in December that the company had successfully completed patient recruitment into its pivotal 52-week Phase III clinical trial of Lupu

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.